17 min
Precision Medicine in Multiple Myeloma EHA Unplugged
-
- Education
Join us for a captivating discussion with Prof Pieter Sonneveld, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, the Netherlands, as he explores the evolution of precision medicine in multiple myeloma.
Prof. Sonneveld outlines the improvements in multiple myeloma treatment over the past decade, describing the progressive addition of targeted therapies such as daratumumab and bispecific antibodies, BiTEs, and CAR-T cells to the therapeutic arsenal.
Discover how treatment selection now hinges on whether a one-off or continuous therapy is most suitable, acknowledging the challenges of limited availability in Europe due to cost considerations. Learn about the outstanding findings from the phase III PERSEUS trial, demonstrating the effectiveness of daratumumab combined with lenalidomide for newly diagnosed transplant-eligible patients and transforming their standard of care.
This interview unveils cutting-edge strategies that are reshaping myeloma prognosis and underscores the importance of early adoption of novel therapies for improved patient outcomes.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Peter Sonneveld
This is the fifth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn More
If you'd like to learn more about Multiple Myeloma, check out the comprehensive EHA - Multiple Myeloma Program on EHA Campus.
Interested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
Join us for a captivating discussion with Prof Pieter Sonneveld, MD, PhD, from Erasmus MC Cancer Institute in Rotterdam, the Netherlands, as he explores the evolution of precision medicine in multiple myeloma.
Prof. Sonneveld outlines the improvements in multiple myeloma treatment over the past decade, describing the progressive addition of targeted therapies such as daratumumab and bispecific antibodies, BiTEs, and CAR-T cells to the therapeutic arsenal.
Discover how treatment selection now hinges on whether a one-off or continuous therapy is most suitable, acknowledging the challenges of limited availability in Europe due to cost considerations. Learn about the outstanding findings from the phase III PERSEUS trial, demonstrating the effectiveness of daratumumab combined with lenalidomide for newly diagnosed transplant-eligible patients and transforming their standard of care.
This interview unveils cutting-edge strategies that are reshaping myeloma prognosis and underscores the importance of early adoption of novel therapies for improved patient outcomes.
Host: Isabel Olivera-Martinez, PhD
Guest: Prof Peter Sonneveld
This is the fifth episode in a series of podcasts covering precision medicine across various disorders; more podcasts will be available in the future. Stay tuned!
Learn More
If you'd like to learn more about Multiple Myeloma, check out the comprehensive EHA - Multiple Myeloma Program on EHA Campus.
Interested in more content related to Precision Medicine? We've got you covered. Check out podcasts, clinical cases, courses, and more on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
17 min